Lasa Supergenerics Limited's Board of Directors approved the company's unaudited financial results for Q3FY26 on February 13, 2026, revealing continued operational and financial challenges. The board meeting, which commenced at 2:00 PM and concluded at 3:15 PM, approved results showing a net loss of Rs 255.47 lakh for the quarter ended December 31, 2025.

Financial Performance Overview

The company's financial performance reflects the severe impact of operational disruptions on its business operations. Revenue from operations declined dramatically to Rs 219.93 lakh in Q3FY26 compared to Rs 3,307.99 lakh in Q3FY25, representing a substantial year-on-year decrease.

Board Meeting and Regulatory Compliance

The Board of Directors meeting held on February 13, 2026, considered and approved the unaudited financial results along with the Limited Review Report from the statutory auditor. The company has submitted integrated filing for the quarter ended December 31, 2025, pursuant to SEBI regulations and BSE/NSE circulars.

Chairman and Managing Director Omkar Herlekar digitally signed the regulatory filings, confirming compliance with SEBI listing obligations and disclosure requirements. The financial results are available on the company's website at www.lasalabs.com and stock exchange websites.

Impact of Fire Incident

The company's operational challenges stem from a major fire incident that occurred on May 18, 2025, at its main manufacturing facility located at Plot No. C-4 in Lote Parshuram Industrial area, Ratnagiri, Maharashtra. This incident has had cascading effects on the company's entire production ecosystem.

The fire caused extensive damage to multiple aspects of the facility, including inventories, property, plant and equipment, and office areas. As this unit served as the central hub for primary production activities, the damage resulted in a complete halt of all production processes.

Exceptional Items and Losses

The fire incident resulted in substantial uninsured losses that have been recognized as exceptional items in the financial statements. The total exceptional loss amounts to Rs 2,057.47 lakh for the nine-month period.

The affected assets were not covered by insurance, amplifying the financial impact on the company. The management has duly informed stock exchanges, the Factory Inspector, and the Office of the Labor Commissioner regarding the suspension of operations.

Auditor's Review and Going Concern

Statutory auditors Gupta Rustagi & Co. provided a limited review report highlighting the company's inability to commence manufacturing activities due to pending statutory clearances and operational constraints. The auditors noted that management is actively exploring alternative options including contract manufacturing arrangements and facility leasing, subject to regulatory approvals.

Additional challenges include dormant bank accounts with a book balance of Rs 7.99 lakh and fixed deposits worth Rs 31.46 lakh as of December 31, 2025, for which confirmations could not be obtained due to dormant status.

LASA Supergenerics Limited has announced a key leadership appointment, with the Board of Directors approving the appointment of Mr. Ganesh Suresh Potdar as Additional Director in the capacity of Executive Director and Occupier of all company units. The decision was made during a board meeting held on January 02, 2026, which commenced at 2:00 p.m. and concluded at 4:00 p.m.

Board Meeting Outcome

The appointment was approved pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the appointment remains subject to approval by members at the ensuing General Meeting or Postal Ballot of the company.

Director Profile and Expertise

Mr. Ganesh Suresh Potdar brings significant operational and commercial expertise to his new role. The following table outlines his key credentials:

Professional Background

Mr. Potdar brings a broad-based understanding of business operations and commercial practices to LASA Supergenerics. His professional expertise includes:

• Exposure to banking-related processes and coordination with financial institutions
• Understanding of routine banking formalities and compliance requirements
• Experience in documentation and compliance-related interactions
• Capability to contribute in financial coordination and operational follow-up matters

Corporate Governance Details

As per the disclosure requirements, Mr. Potdar currently holds no directorships in other public companies (excluding foreign, private, and Section 8 companies). He also has no memberships or chairmanships of Audit and Stakeholders' Relationships Committees across public companies. There are no inter-se relationships between Mr. Potdar and other directors of the company.

Regulatory Compliance

The appointment follows all regulatory requirements under SEBI guidelines. The company has made the information available on its website at www.lasalabs.com and on stock exchange websites. The appointment notification was signed by Omkar Herlekar, Chairman and Managing Director of LASA Supergenerics Limited.